Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan

Results of the ASSET studies

Robyn J. Barst, Kamal K. Mubarak, Roberto F. MacHado, Kenneth Ataga, Raymond L. Benza, Oswaldo Castro, Robert Naeije, Namita Sood, Paul S. Swerdlow, Mariana Hildesheim, Mark T. Gladwin

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40% mortality at 40 months. To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), respectively. Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16. The studies were terminated due to slow site initiation and patient enrolment (n = 26). Bosentan appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0·006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0·07) and between 6MWD and right atrial pressure (P = 0·08). In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0·06). Due to limited sample sizes, efficacy endpoints were not analysed. However, in both studies, non-significant increases in CO were observed with bosentan compared to placebo. Similarly, non-significant decreases in PVR were observed with bosentan. Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087.

Original languageEnglish (US)
Pages (from-to)426-435
Number of pages10
JournalBritish Journal of Haematology
Volume149
Issue number3
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Pulmonary Hypertension
Carbon Monoxide
Hemodynamics
Exercise
Sample Size
Placebos
Atrial Pressure
Cardiac Output
Vascular Resistance
bosentan
Safety
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan : Results of the ASSET studies. / Barst, Robyn J.; Mubarak, Kamal K.; MacHado, Roberto F.; Ataga, Kenneth; Benza, Raymond L.; Castro, Oswaldo; Naeije, Robert; Sood, Namita; Swerdlow, Paul S.; Hildesheim, Mariana; Gladwin, Mark T.

In: British Journal of Haematology, Vol. 149, No. 3, 01.05.2010, p. 426-435.

Research output: Contribution to journalArticle

Barst, RJ, Mubarak, KK, MacHado, RF, Ataga, K, Benza, RL, Castro, O, Naeije, R, Sood, N, Swerdlow, PS, Hildesheim, M & Gladwin, MT 2010, 'Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: Results of the ASSET studies', British Journal of Haematology, vol. 149, no. 3, pp. 426-435. https://doi.org/10.1111/j.1365-2141.2010.08097.x
Barst, Robyn J. ; Mubarak, Kamal K. ; MacHado, Roberto F. ; Ataga, Kenneth ; Benza, Raymond L. ; Castro, Oswaldo ; Naeije, Robert ; Sood, Namita ; Swerdlow, Paul S. ; Hildesheim, Mariana ; Gladwin, Mark T. / Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan : Results of the ASSET studies. In: British Journal of Haematology. 2010 ; Vol. 149, No. 3. pp. 426-435.
@article{a81c7967b0de4a108b33e17ae5350769,
title = "Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: Results of the ASSET studies",
abstract = "Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40{\%} mortality at 40 months. To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), respectively. Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16. The studies were terminated due to slow site initiation and patient enrolment (n = 26). Bosentan appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0·006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0·07) and between 6MWD and right atrial pressure (P = 0·08). In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0·06). Due to limited sample sizes, efficacy endpoints were not analysed. However, in both studies, non-significant increases in CO were observed with bosentan compared to placebo. Similarly, non-significant decreases in PVR were observed with bosentan. Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087.",
author = "Barst, {Robyn J.} and Mubarak, {Kamal K.} and MacHado, {Roberto F.} and Kenneth Ataga and Benza, {Raymond L.} and Oswaldo Castro and Robert Naeije and Namita Sood and Swerdlow, {Paul S.} and Mariana Hildesheim and Gladwin, {Mark T.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1111/j.1365-2141.2010.08097.x",
language = "English (US)",
volume = "149",
pages = "426--435",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan

T2 - Results of the ASSET studies

AU - Barst, Robyn J.

AU - Mubarak, Kamal K.

AU - MacHado, Roberto F.

AU - Ataga, Kenneth

AU - Benza, Raymond L.

AU - Castro, Oswaldo

AU - Naeije, Robert

AU - Sood, Namita

AU - Swerdlow, Paul S.

AU - Hildesheim, Mariana

AU - Gladwin, Mark T.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40% mortality at 40 months. To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), respectively. Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16. The studies were terminated due to slow site initiation and patient enrolment (n = 26). Bosentan appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0·006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0·07) and between 6MWD and right atrial pressure (P = 0·08). In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0·06). Due to limited sample sizes, efficacy endpoints were not analysed. However, in both studies, non-significant increases in CO were observed with bosentan compared to placebo. Similarly, non-significant decreases in PVR were observed with bosentan. Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087.

AB - Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is associated with 40% mortality at 40 months. To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-week studies were initiated. Safety concerns are particularly relevant in SCD due to comorbid conditions. ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), respectively. Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16. The studies were terminated due to slow site initiation and patient enrolment (n = 26). Bosentan appeared to be well tolerated. Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0·006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0·07) and between 6MWD and right atrial pressure (P = 0·08). In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0·06). Due to limited sample sizes, efficacy endpoints were not analysed. However, in both studies, non-significant increases in CO were observed with bosentan compared to placebo. Similarly, non-significant decreases in PVR were observed with bosentan. Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087.

UR - http://www.scopus.com/inward/record.url?scp=77950820615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950820615&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08097.x

DO - 10.1111/j.1365-2141.2010.08097.x

M3 - Article

VL - 149

SP - 426

EP - 435

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -